Elena V. Do, MD: Aflibercept 8 mg Therapeutic Benefit for DME in PHOTON Trial.

Published Date: 04 May 2023

Do talks about the advantages of aflibercept 8 mg for DME in the phase 2/3 PHOTON trial, showing non-inferiority in BCVA compared to aflibercept 2 mg and no new safety concerns, at ARVO 2023.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

In Acute Myeloid Leukemia Diagnosed Recently, FLT3 Inhibitor Is Very Effective.

2.

Increased Data Support Active Monitoring for Low-Risk Prostate Cancer.

3.

Temsirolimus Plus Chemotherapy Fails in Rare Childhood Cancer

4.

A prostate cancer risk prediction algorithm could help target men at highest risk

5.

A smartphone app enhances the tracking of recovery following breast and gynecologic oncology surgery, according to JAMA.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot